President and Chief Medical Officer at Sarah Cannon Research Institute | Advancing Therapies Through Clinical Research #Oncology #Healthcare #CancerResearch
Nashville, TN
Joined March 2011
- Tweets138
- Following753
- Followers3.1K
- Likes6.1K
Fantastic discussion!
🎯 #ESMO26 | Excellent discussion by @benlevylungdoc on SARON and PERSEE!
Two trials, two important lessons for advanced NSCLC.
🔹 SARON: Consolidative radiotherapy improved PFS and local disease control in oligo metastatic NSCLC, but no OS benefit (HR 0.99).
🔹 PERSEE: Pembrolizumab + chemo met its primary endpoint PFS but not OS though numerically better (not powered for OS) in PD-L1 ≥50% NSCLC.
Key messages from @benlevylungdoc :
• Oligometastatic disease needs better biological definition, beyond the number of lesions.
• Treatment intensification should be guided by better patient selection.
• More treatment does not automatically mean better outcomes!
- Lower threshold to add chemo to pembro in PD-L1 >50%
👏 A thoughtful discussion with practical implications for our clinics.
#ESMOAmbassador #LungCancer #NSCLC
David R. Spigel, MD, FASCO retweeted
Outstanding presentation by our very own @DanaFarber @sands_jacob ! DeLLphi-305: tarlatamab + durvalumab vs durvalumab as 1L maintenance in ES-SCLC improved median OS to 21.1 vs 12.7 months (HR 0.42). A major advance for patients with SCLC! #ESMO26 @oncoalert @myESMO
David R. Spigel, MD, FASCO retweeted
Presented at #ESMO26:
Among patients with PD-L1–negative advanced nonsquamous non–small-cell lung cancer, progression-free survival was longer with sacituzumab tirumotecan plus pembrolizumab than with chemotherapy plus pembrolizumab (15.0 vs. 5.7 months). Full phase 3 OptiTROP-Lung06 trial results: nej.md/4Bo3liu
@myESMO
ALT A graph from the Original Article " Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC.” The trial name, OptiTROP-Lung06, is in parentheses after the title. The graph shows progression-free survival as assessed by blinded independent central review. The trial results are being presented at the European Society for Medical Oncology 2026 Congress. The logo of the New England Journal of Medicine is at the bottom.
David R. Spigel, MD, FASCO retweeted
At #ESMO26, SCRI will present 85+ abstracts and presentations across antibody drug conjugates, immunotherapies, and bispecific antibodies, with work from 40 authors across our network of research sites. scri.com/news/sarah-cannon-r…
David R. Spigel, MD, FASCO retweeted
Presented at #ESMO26:
In patients with previously treated advanced non–small-cell lung cancer with a 𝘒𝘙𝘈𝘚 G12C mutation, median progression-free survival was 9.8 months with the KRAS G12C inhibitor divarasib and 5.7 months with sotorasib or adagrasib. Full phase 3 Krascendo 1 trial results: nej.md/4BiCvbk
@myESMO
ALT A graph from the Original Article "Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC.” The trial name, Krascendo 1, is in parentheses after the title. The graph shows progression-free survival in the full analysis population. The trial results are being presented at the European Society for Medical Oncology 2026 Congress. The logo of the New England Journal of Medicine is at the bottom.
David R. Spigel, MD, FASCO retweeted
Proud to contribute to the Phase III Krascendo 1 study, presented at #ESMO2026 and published in @NEJM. Co-author @BoWangMD1 called the findings “potentially practice-changing” for patients with KRAS G12C-mutated lung cancer. scri.com/news/sarah-cannon-r…
David R. Spigel, MD, FASCO retweeted
Expanding access to clinical trials remains a critical priority in oncology research. @SPremji7866 of SCRI recently shared insights with @TargetedOnc on the importance of community-based research and the evolving breast cancer landscape.
targetedonc.com/view/dr-prem…
David R. Spigel, MD, FASCO retweeted
Congratulations to @IMFmyeloma on the launch of the US Myeloma Network! We are honored to serve as the CRO and support clinical trials designed to advance research and expand opportunities for patients w/ multiple myeloma. Looking forward to this collaboration in #CancerResearch.
I am proud to announce the launch of the US Myeloma Network (USMN) by the International Myeloma Foundation. @IMFmyeloma
The USMN will conduct clinical trials including phase III randomized controlled trials. @JNJInnovMed is our first industry partner. @SarahCannonDocs will be our CRO.
@SagarLonialMD @TomMartinMD @szusmani @myelomaMD @NikhilMunshiMD
prnewswire.com/news-releases…
David R. Spigel, MD, FASCO retweeted
In a recent interview w/ @Blood_Cancers, Dr. Hans Lee of @SCRIOncology discusses how cellular therapies are changing care for patients with advanced multiple myeloma and the importance of expanding access.
Read the Q&A:
The next step in advanced #myeloma is improving access to therapies such as CAR-T and bispecific antibodies, according to Hans Lee, MD, of @SarahCannonDocs.
📖 Read more from this exclusive Q&A: buff.ly/5qX7rQu
David R. Spigel, MD, FASCO retweeted
Breaking from #ASCO26: The Phase 3 #frontMIND trial successfully hit its primary endpoint! 🚨
Adding tafasitamab + lenalidomide to standard R-CHOP significantly improves PFS in newly diagnosed high-risk #DLBCL.
Full story: bit.ly/3REcctU
David R. Spigel, MD, FASCO retweeted
What research is generating buzz heading into #ASCO26? In a new @biospace feature, Dr. @MeredithPelster of Sarah Cannon Research Institute shares insights on promising advances in pancreatic cancer research and targeted therapies.
biospace.com/drug-developmen…
David R. Spigel, MD, FASCO retweeted
Inspiring discussion around how we can have greater impact in the community for veterans w/ our colleagues at #FCS & the VA @Dee_Anna_Smith @LucioGordanMD #ASCO26
David R. Spigel, MD, FASCO retweeted
Meet SCRI experts at #ASCO26 for a lymphoma session led by @KrishPatelMD . Join the conversation and learn how we are advancing research for patients.
David R. Spigel, MD, FASCO retweeted
SCRI contributed to research leading to upcoming plenary on Daraxonrasib, a RAS(ON) multi-selective inhibitor, vs chemotherapy in previously treated patients with met pancreatic adenocarcinoma: Primary analysis from the phase 3 RASolute 302 @MeredithPelster @SCRIOncology #ASCO26
David R. Spigel, MD, FASCO retweeted
Coming up! @MLJohnsonMD2 is coauthor on Event-Free Survival with Adjuvant Selpercatinib in Stage IB-IIIA RET Fusion-Positive NSCLC: Primary Results of the Phase 3 LIBRETTO-432 Trial that will be presented during the Plenary Session at 2:13 p.m. CDT in Hall B1 #ASCO26
David R. Spigel, MD, FASCO retweeted
@SCRIOncology was honored to co-host the @AmericanCancer ACS gala in Nashville.
Amazing fundraising effort benefitting patients facing cancer.
@DavidRSpigel
@MLJohnsonMD2
@MeredithMcKean
@ErikaHamilton9
@BGarmezy
@MeredithPelster
@SPremji7866
@SarahCannonDocs
David R. Spigel, MD, FASCO retweeted
🎪 🤡 🐘 🦁
Happy Halloween from the circus!
@MLJohnsonMD2 @DavidRSpigel @VivekSubbiah @BurrisSkip @SarahCannonDocs
David R. Spigel, MD, FASCO retweeted
🚨🚀Pleased to shared with the Universe 👉HOT OFF THE PRESS👉Simultaneously published with the NEW #ESMO25 @myESMO Tumour Agnostic Tack👉 "Rethinking Cancer Drug Development through Tumor-Agnostic Precision Medicine" @AACR journal @CD_AACR @OncoAlert 👉 Read this paper that will be presented at the special session at ESMO
aacrjournals.org/cancerdisco…
David R. Spigel, MD, FASCO retweeted
📅 We're counting down until #ESMO25 kicks off in Berlin tomorrow!
🗨️ Don't miss this interview with @StephenVLiu, who discusses anticipated thoracic oncology highlights of the meeting!
➡️ Watch now: buff.ly/mqoXWoA
#lcsm #NSCLC #SCLC #ESMO2025 @myESMO
